PURPOSE AND BACKGROUND: This is a report of a 53 year-old man with a glioblastoma multiforme (GBM) treated with an excessive dose of temozolomide (TMZ). METHODS: This is a single case review of all clinically relevant records. O6-methylguanine-DNA methyltransferase activity was determined by a biochemical assay. RESULTS: Following conventional radiotherapy (RT) without concurrent chemotherapy, the patient received 5,500 mg of TMZ over 2 days. At the standard dose of 200 mg/m2/day his total 5-day dose should have been 1,940 mg. Acutely he had nausea, vomiting and diarrhea for 2 days which cleared. The dominant severe toxicity was pancytopenia between one and four weeks after TMZ which was complicated by secondary infections that were successfully managed. Transient transaminitis occurred but there were no significant pulmonary, renal or other systemic toxicities. His progression free survival was 22 months and overall survival 24 months. CONCLUSION: His outcome suggests that TMZ may prove to be a good agent for dose-escalation trials with hematopoietic stem cell rescue.
PURPOSE AND BACKGROUND: This is a report of a 53 year-old man with a glioblastoma multiforme (GBM) treated with an excessive dose of temozolomide (TMZ). METHODS: This is a single case review of all clinically relevant records. O6-methylguanine-DNA methyltransferase activity was determined by a biochemical assay. RESULTS: Following conventional radiotherapy (RT) without concurrent chemotherapy, the patient received 5,500 mg of TMZ over 2 days. At the standard dose of 200 mg/m2/day his total 5-day dose should have been 1,940 mg. Acutely he had nausea, vomiting and diarrhea for 2 days which cleared. The dominant severe toxicity was pancytopenia between one and four weeks after TMZ which was complicated by secondary infections that were successfully managed. Transient transaminitis occurred but there were no significant pulmonary, renal or other systemic toxicities. His progression free survival was 22 months and overall survival 24 months. CONCLUSION: His outcome suggests that TMZ may prove to be a good agent for dose-escalation trials with hematopoietic stem cell rescue.
Authors: E S Newlands; S M O'Reilly; M G Glaser; M Bower; H Evans; C Brock; M H Brampton; I Colquhoun; P Lewis; J M Rice-Edwards; R D Illingworth; P G Richards Journal: Eur J Cancer Date: 1996-12 Impact factor: 9.162
Authors: Jennifer A Quinn; Annick Desjardins; Jon Weingart; Henry Brem; M Eileen Dolan; Shannon M Delaney; James Vredenburgh; Jeremy Rich; Allan H Friedman; David A Reardon; John H Sampson; Anthony E Pegg; Robert C Moschel; Robert Birch; Roger E McLendon; James M Provenzale; Sridharan Gururangan; Janet E Dancey; Jill Maxwell; Sandra Tourt-Uhlig; James E Herndon; Darell D Bigner; Henry S Friedman Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: D R Adkins; R Irvin; J Kuhn; D H Boldt; G D Roodman; D Salzman; C Freytes; D D Von Hoff; C F LeMaistre Journal: Invest New Drugs Date: 1993 May-Aug Impact factor: 3.850
Authors: E K Mbidde; P J Selby; T J Perren; D P Dearnaley; A Whitton; S Ashley; P Workman; H J Bloom; T J McElwain Journal: Br J Cancer Date: 1988-12 Impact factor: 7.640
Authors: E S Newlands; G R Blackledge; J A Slack; G J Rustin; D B Smith; N S Stuart; C P Quarterman; R Hoffman; M F Stevens; M H Brampton Journal: Br J Cancer Date: 1992-02 Impact factor: 7.640
Authors: Dagmar Beier; Beate Schriefer; Konstantin Brawanski; Peter Hau; Joachim Weis; Jörg B Schulz; Christoph P Beier Journal: J Neurooncol Date: 2012-04-29 Impact factor: 4.130
Authors: Chen Fang; Kui Wang; Zachary R Stephen; Qingxin Mu; Forrest M Kievit; Daniel T Chiu; Oliver W Press; Miqin Zhang Journal: ACS Appl Mater Interfaces Date: 2015-03-18 Impact factor: 9.229